Novartis targets NICE nod to make Kisqali reinforce its 'leadership in cancer research'

27 September 2017

The European Commission (EC) approval of a combination involving Kisqali (ribociclib) for a large breast cancer indication last month led a senior executive from Swiss pharma giant Novartis (NOVN: VX) to proclaim that it proved the company’s ‘recognized leadership in cancer research’.

In an age when gaining reimbursement is becoming as important as regulatory approval, however, what executives know is the crowning moment for an innovative treatment is the agreement of health authorities to pay for it.

"We’re hearing a lot of excitement from physicians, and we believe the same level of excitement will also come from the health authorities"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK